PMID- 35747945
OWN - NLM
STAT- MEDLINE
DCOM- 20221004
LR  - 20221213
IS  - 2211-5463 (Electronic)
IS  - 2211-5463 (Linking)
VI  - 12
IP  - 10
DP  - 2022 Oct
TI  - Generation of universal natural killer cells from a cryopreserved cord blood 
      mononuclear cell-derived induced pluripotent stem cell library.
PG  - 1771-1781
LID - 10.1002/2211-5463.13460 [doi]
AB  - Natural killer (NK) cells play a key role in innate immunity and are regarded as 
      a promising candidate for cellular immunotherapy. Natural killer cells may be 
      generated from different sources, including induced pluripotent stem cells 
      (iPSCs); these stem cells produce an abundant amount of NK cells to meet the 
      needs of a wide range of clinical applications. Autologous iPSCs are expensive 
      and labor-intensive to prepare, while allogeneic iPSCs require human leukocyte 
      antigen (HLA) matched cells to avoid the risk of immune rejection. In the current 
      study, we prepared HLA-matched iPSCs using HLA common haplotype homozygous (HLAh) 
      donors from cryopreserved human cord blood (CB) sourced from the Tianjin Cord 
      Blood Public Bank. This approach was designed to generate a CB-derived iPSC 
      library from HLAh donors and use it to produce off-the-shelf NK cells. Starting 
      with readily available cryopreserved CB mononuclear cells (cryoCBMCs), we 
      produced cryoCBMC-derived iPSCs (cryoCB-iPSCs). These cryoCB-iPSCs were induced 
      to generate embryoid bodies (EBs) using an improved 3D suspension culture method, 
      and induced NK (iNK) cells were differentiated from EBs. iNK cells expressed 
      specific surface markers of NK cells, exhibited cytotoxicity comparable with NK 
      cells generated from CB (CB-NK) and peripheral blood (PB-NK), and expressed lower 
      levels of KIRs and HLA-DR compared to CB-NK and PB-NK. Taken together, we have 
      shown that an iPSC library can be established from HLAh cryoCBMCs, and 
      cryoCB-iPSCs can be used to generate a large number of 'universal' NK cells for 
      future clinical applications.
CI  - (c) 2022 The Authors. FEBS Open Bio published by John Wiley & Sons Ltd on behalf of 
      Federation of European Biochemical Societies.
FAU - Du, Wei
AU  - Du W
AUID- ORCID: 0000-0001-8705-1983
AD  - Union Stem Cell & Gene Engineering Co., LTD, Tianjin, China.
AD  - School of Medicine, Nankai University, Tianjin, China.
AD  - Tianjin Key Laboratory of Blood Cell Therapy Technology, China.
AD  - National Stem Cell Product Industrialization Base, State Industrial Base for Stem 
      Cell Engineering Products, Tianjin, China.
FAU - Cui, Lijuan
AU  - Cui L
AD  - Union Stem Cell & Gene Engineering Co., LTD, Tianjin, China.
AD  - Tianjin Key Laboratory of Blood Cell Therapy Technology, China.
AD  - National Stem Cell Product Industrialization Base, State Industrial Base for Stem 
      Cell Engineering Products, Tianjin, China.
FAU - Zhang, Jinmei
AU  - Zhang J
AD  - Union Stem Cell & Gene Engineering Co., LTD, Tianjin, China.
AD  - Tianjin Key Laboratory of Blood Cell Therapy Technology, China.
AD  - National Stem Cell Product Industrialization Base, State Industrial Base for Stem 
      Cell Engineering Products, Tianjin, China.
FAU - Zhang, Hua
AU  - Zhang H
AD  - Union Stem Cell & Gene Engineering Co., LTD, Tianjin, China.
AD  - Tianjin Key Laboratory of Blood Cell Therapy Technology, China.
AD  - National Stem Cell Product Industrialization Base, State Industrial Base for Stem 
      Cell Engineering Products, Tianjin, China.
FAU - Liu, Rongzhi
AU  - Liu R
AD  - Union Stem Cell & Gene Engineering Co., LTD, Tianjin, China.
AD  - Tianjin Key Laboratory of Blood Cell Therapy Technology, China.
AD  - National Stem Cell Product Industrialization Base, State Industrial Base for Stem 
      Cell Engineering Products, Tianjin, China.
FAU - Yang, Wenling
AU  - Yang W
AD  - Union Stem Cell & Gene Engineering Co., LTD, Tianjin, China.
AD  - National Stem Cell Product Industrialization Base, State Industrial Base for Stem 
      Cell Engineering Products, Tianjin, China.
FAU - Zhang, Yu
AU  - Zhang Y
AD  - Union Stem Cell & Gene Engineering Co., LTD, Tianjin, China.
AD  - Tianjin Key Laboratory of Blood Cell Therapy Technology, China.
AD  - National Stem Cell Product Industrialization Base, State Industrial Base for Stem 
      Cell Engineering Products, Tianjin, China.
AD  - Vcanbio Cell & Gene Engineering Co., Ltd, Tianjin, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220701
PL  - England
TA  - FEBS Open Bio
JT  - FEBS open bio
JID - 101580716
RN  - 0 (HLA Antigens)
RN  - 0 (Inducible T-Cell Co-Stimulator Protein)
SB  - IM
MH  - Fetal Blood/metabolism
MH  - HLA Antigens
MH  - Humans
MH  - *Induced Pluripotent Stem Cells/metabolism
MH  - Inducible T-Cell Co-Stimulator Protein/metabolism
MH  - Killer Cells, Natural
PMC - PMC9527588
OTO - NOTNLM
OT  - cell therapy
OT  - cryopreserved cord blood mononuclear cells
OT  - induced pluripotent stem cells
OT  - natural killer cells
COIS- The authors declare no conflict of interest.
EDAT- 2022/06/25 06:00
MHDA- 2022/10/05 06:00
PMCR- 2022/07/01
CRDT- 2022/06/24 02:43
PHST- 2022/04/08 00:00 [revised]
PHST- 2021/12/17 00:00 [received]
PHST- 2022/06/22 00:00 [accepted]
PHST- 2022/06/25 06:00 [pubmed]
PHST- 2022/10/05 06:00 [medline]
PHST- 2022/06/24 02:43 [entrez]
PHST- 2022/07/01 00:00 [pmc-release]
AID - FEB413460 [pii]
AID - 10.1002/2211-5463.13460 [doi]
PST - ppublish
SO  - FEBS Open Bio. 2022 Oct;12(10):1771-1781. doi: 10.1002/2211-5463.13460. Epub 2022 
      Jul 1.